Diseases & conditions › Alzheimer's Disease
Neurological

Alzheimer's Disease

Last updated: September 2026 AI-generated 248 views
Rate this page
★ ★ ★ ★ ★
This information is for educational purposes only. Always consult a qualified medical professional before making any health decisions.
Overview

A progressive neurodegenerative disorder that causes problems with memory, thinking, and behavior. It is the most common cause of dementia in older adults.

Symptoms

Memory loss that disrupts daily life, difficulty completing familiar tasks, confusion with time or place, problems with words, changes in mood and personality.

Causes

Accumulation of beta-amyloid plaques and tau tangles in the brain. Risk factors include age, family history, APOE-e4 genotype, cardiovascular disease, and head injury.

Diagnosis

Diagnosis information coming soon.

Treatment

Cholinesterase inhibitors (donepezil, rivastigmine), NMDA receptor antagonists (memantine), anti-amyloid antibody therapies, lifestyle interventions including exercise, cognitive engagement, and management of cardiovascular risk factors.

Clinical trials
Completed
18F-AV-1451 PET Imaging in the Preclinical, Prodromal and Dementia Phases of Alzheimer's Disease
Completed · Avid Radiopharmaceuticals · NCT04468347
Completed
A Cohort of Outpatients From French Research Memory Centers in Order to Improve Knowledge on Alzheimer's Disease and Related Disorders
Completed · University Hospital, Bordeaux · NCT01926249
Completed
A Phase 1, Safety, Tolerability, Single-ascending Dose, Multiple-ascending Dose, Food Effect, and Pharmacokinetic Study of TML-6 in Healthy Volunteers
Completed · Merry Life Biomedical Co., Ltd. · NCT06562114
Active, not recruiting
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease
Active not recruiting · Eisai Inc. · NCT03887455
Completed
A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose of Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NH280105 in Healthy Adult Participants
Completed · Jiangsu Nhwa Pharmaceutical Co., Ltd. · NCT06870058
Completed
A Randomized, Placebo-Controlled, Double-blind, Parallel-Group, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally-administered NGP 555 in Healthy Subjects
Completed · NeuroGenetic Pharmaceuticals Inc · NCT02537938
Completed
Circuit-specific Neuromodulation for the Treatment of Apathy in Alzheimer's Disease
Terminated · Massachusetts General Hospital · NCT05389644
Completed
Donanemab in early symptomatic Alzheimer's disease (TRAILBLAZER-ALZ 2)
Completed · Eli Lilly and Company · NCT04437511
Recruiting
Donanemab long-term cognitive outcomes study
Recruiting · Eli Lilly and Company · NCT05823584
Active, not recruiting
Korean Brain Aging Study for Early Diagnosis and Prediction of Alzheimer's disease2
Active not recruiting · Seoul National University Hospital · NCT05138263
Recruiting
Neurologic Bone Marrow Derived Stem Cell Treatment Study
Recruiting · MD Stem Cells · NCT02795052
Completed
Support by Singing Sessions on Physical and Moral Pain : Assessment of Its Effectiveness in Alzheimer's Disease. Multicenter Study LACME
Completed · Centre Hospitalier Universitaire de Saint Etienne · NCT02670993
How would you rate this page?
Your feedback helps us improve the quality of our content.
★ ★ ★ ★ ★
What did you like about this page?
What did you not like about this page?
Is there anything else you'd like to see covered?
Report an error
All reports are reviewed before any changes are made.
What type of error are you reporting?
Which section does this relate to?
Please describe the error
Be as specific as possible — include the correct information if you know it.
Highlight mode — select the text containing the error
Click and drag over the relevant text, then click Confirm.
✓
Thank you
Your response helps us improve the quality of this page.